Cargando…

Early Administration of the Phytocannabinoid Cannabidivarin Prevents the Neurobehavioral Abnormalities Associated with the Fmr1-KO Mouse Model of Fragile X Syndrome

Phytocannabinoids, including the non-addictive cannabis component cannabidivarin (CBDV), have been reported to hold therapeutic potential in several neurodevelopmental disorders (NDDs). Nonetheless, the therapeutic value of phytocannabinoids for treating Fragile X syndrome (FXS), a major NDD, remain...

Descripción completa

Detalles Bibliográficos
Autores principales:	Premoli, Marika, Fyke, William, Bellocchio, Luigi, Lemaire, Valerie, Wolley-Roberts, Marie, Bontempi, Bruno, Pietropaolo, Susanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10416983/ https://www.ncbi.nlm.nih.gov/pubmed/37566006 http://dx.doi.org/10.3390/cells12151927

Ejemplares similares

Long-term behavioral effects of prenatal stress in the Fmr1-knock-out mouse model for fragile X syndrome
por: Petroni, Valeria, et al.
Publicado: (2022)

The Impact of Mild Chronic Stress and Maternal Experience in the Fmr1 Mouse Model of Fragile X Syndrome
por: Subashi, Enejda, et al.
Publicado: (2023)

Autistic-like behavioral effects of prenatal stress in juvenile Fmr1 mice: the relevance of sex differences and gene–environment interactions
por: Petroni, Valeria, et al.
Publicado: (2022)

Hyperacusis in the Adult Fmr1-KO Mouse Model of Fragile X Syndrome: The Therapeutic Relevance of Cochlear Alterations and BKCa Channels
por: Ferraguto, Celeste, et al.
Publicado: (2023)

Rescue of fragile X syndrome phenotypes in Fmr1 KO mice by a BKCa channel opener molecule
por: Hébert, Betty, et al.
Publicado: (2014)

FMR1 and Autism, an Intriguing Connection Revisited
por: Fyke, William, et al.
Publicado: (2021)

Comparative Behavioral Phenotypes of Fmr1 KO, Fxr2 Het, and Fmr1 KO/Fxr2 Het Mice
por: Saré, Rachel Michelle, et al.
Publicado: (2019)

Reversal of Fragile X Phenotypes by Manipulation of AβPP/Aβ Levels in Fmr1(KO) Mice
por: Westmark, Cara J., et al.
Publicado: (2011)

Neurocognitive endophenotypes in CGG KI and Fmr1 KO mouse models of Fragile X-Associated disorders: an analysis of the state of the field
por: Hunsaker, Michael R.
Publicado: (2013)

Sub-synaptic, multiplexed analysis of proteins reveals Fragile X related protein 2 is mislocalized in Fmr1 KO synapses
por: Wang, Gordon X, et al.
Publicado: (2016)

Efficient Delivery of FMR1 across the Blood Brain Barrier Using AAVphp Construct in Adult FMR1 KO Mice Suggests the Feasibility of Gene Therapy for Fragile X Syndrome
por: Chadman, Kathryn K., et al.
Publicado: (2023)

CNS-dominant human FMRP isoform rescues seizures, fear, and sleep abnormalities in Fmr1-KO mice
por: Wong, Hayes, et al.
Publicado: (2023)

A Genotype-Phenotype Study of High-Resolution FMR1 Nucleic Acid and Protein Analyses in Fragile X Patients with Neurobehavioral Assessments
por: Budimirovic, Dejan B., et al.
Publicado: (2020)

Fmr1 KO Mice as a Possible Model of Autistic Features
por: Bernardet, Maude, et al.
Publicado: (2006)

Impact of FMR1 Premutation on Neurobehavior and Bioenergetics in Young Monozygotic Twins
por: Napoli, Eleonora, et al.
Publicado: (2018)

Homeostatic Intrinsic Plasticity Is Functionally Altered in Fmr1 KO Cortical Neurons
por: Bülow, Pernille, et al.
Publicado: (2019)

Gamma power abnormalities in a Fmr1-targeted transgenic rat model of fragile X syndrome
por: Kozono, Naoki, et al.
Publicado: (2020)

NMD abnormalities during brain development in the Fmr1-knockout mouse model of fragile X syndrome
por: Kurosaki, Tatsuaki, et al.
Publicado: (2021)

Hyperexcitability and Loss of Feedforward Inhibition Contribute to Aberrant Plasticity in the Fmr1KO Amygdala
por: Svalina, Matthew N., et al.
Publicado: (2021)

Reevaluation of FMR1 Hypermethylation Timing in Fragile X Syndrome
por: Mor-Shaked, Hagar, et al.
Publicado: (2018)

A sound-driven cortical phase-locking change in the Fmr1 KO mouse requires Fmr1 deletion in a subpopulation of brainstem neurons
por: Holley, Andrew J., et al.
Publicado: (2022)

In Vivo Volume Dynamics of Dendritic Spines in the Neocortex of Wild-Type and Fmr1 KO Mice
por: Ishii, Kazuhiko, et al.
Publicado: (2018)

Evaluation of FMR4, FMR5 and FMR6 Expression Levels as Non-Invasive Biomarkers for the Diagnosis of Fragile X-Associated Primary Ovarian Insufficiency (FXPOI)
por: Alvarez-Mora, Maria Isabel, et al.
Publicado: (2022)

The Oxidation of Phytocannabinoids to Cannabinoquinoids
por: Caprioglio, Diego, et al.
Publicado: (2020)

Antibacterial Effects of Phytocannabinoids
por: Scott, Cassidy, et al.
Publicado: (2022)

Phytocannabinoids in the Pharmacotherapy of Psoriasis
por: Wroński, Adam, et al.
Publicado: (2023)

Depressed nNOS expression during spine transition in the developing hippocampus of FMR1 KO mice
por: Xu, Qin, et al.
Publicado: (2012)

Impaired Adaptation and Laminar Processing of the Oddball Paradigm in the Primary Visual Cortex of Fmr1 KO Mouse
por: Pak, Alexandr, et al.
Publicado: (2021)

Review of the neurological benefits of phytocannabinoids
por: Maroon, Joseph, et al.
Publicado: (2018)

Spontaneous Coronary Artery Dissection in Females With the Fragile X FMR1 Premutation
por: McKenzie, Forrest J., et al.
Publicado: (2020)

Pirenperone relieves the symptoms of fragile X syndrome in Fmr1 knockout mice
por: Kim, Yujeong, et al.
Publicado: (2022)

Testing Fmr1(KO) Phenotypes in Response to GSK3 Inhibitors: SB216763 versus AFC03127
por: Westmark, Pamela R., et al.
Publicado: (2021)

Largely unaffected auditory and visual sensory processing phenotypes in the evoked potentials of Fmr1 KO2 mice
por: Kat, Renate, et al.
Publicado: (2022)

Evaluating the effect of R-Baclofen and LP-211 on autistic behavior of the BTBR and Fmr1-KO mouse models
por: Sharghi, Shirin, et al.
Publicado: (2023)

Ultrasonic Vocalizations in Adult C57BL/6J Mice: The Role of Sex Differences and Repeated Testing
por: Premoli, Marika, et al.
Publicado: (2022)

The anticonvulsant phytocannabinoids CBGVA and CBDVA inhibit recombinant T-type channels
por: Udoh, Michael, et al.
Publicado: (2022)

Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression
por: Amada, Naoki, et al.
Publicado: (2013)

Cannabis in epilepsy: From clinical practice to basic research focusing on the possible role of cannabidivarin
por: Morano, Alessandra, et al.
Publicado: (2016)

Protective Effects of Cannabidivarin and Cannabigerol on Cells of the Blood–Brain Barrier Under Ischemic Conditions
por: Stone, Nicole L., et al.
Publicado: (2021)

Comparative assessment of antimicrobial, antiradical and cytotoxic activities of cannabidiol and its propyl analogue cannabidivarin
por: Russo, Chiara, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_bba4pag7c65b41h44a3e541mo7